Search
for
Sort by
Research 91–120 of 1000+
- Dermatological Drugs, Topical Agents, and Cosmetics
- PROTACs in 2025: from the laboratory concept to clinical breakthrough
- A superb way to split hairs
- The Enticing Path of miR Therapeutics: Difficult but Not without Prospects
- Successes and failures of evidence based urology
- News in brief
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- Non-hemorrhage-related adverse effects of rivaroxaban
- Alopecia - the search for novel agents continues
- A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds
- The role of dutasteride in the treatment of benign prostatic obstruction and related conditions
- Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
- Redefining hormone resistance in prostate cancer
- Therapeutic applications and pharmacoeconomics of microneedle technology
- The role of androgens in hormone replacement therapy
- Towards a consensus potency assay for mesenchymal stromal cells: a matrix analysis of cell source, donor variability and inflammatory stimuli to refine surrogate markers of immunomodulation
- Provenge is Talk of GU Malignancies Congress
- Prostate cancer update: 2007
- Solubilization and Solid‐State Characterization of a Poorly Soluble 5‐α Reductase Inhibitor
- Hair characteristics and androgenetic alopecia in Koreans
- Sacituzumab Govitecan-Hziy (Trodelvy™)
- Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia
- Aldesleukin
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia
- Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double‐blind, placebo‐controlled, phase 1B clinical trial
- A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
- Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 609 Topical Sandalore®, a specific OR2AT4-stimulating odorant, ameliorates female telogen effluvium: Randomized, double-blinded, placebo-controlled clinical trial